NASD · Healthcare · Medical Devices · USA
Dexcom Inc is a large cap company (market value between $10 billion and $200 billion) in the Medical Devices industry.
Dexcom is a medical device company that designs, develops, and commercializes continuous glucose monitoring systems for managing diabetes and metabolic health. Its products include CGM systems for people with diabetes and Stelo, an over-the-counter glucose biosensor for adults with prediabetes and Type diabetes not using insulin. The company serves patients, caregivers, and clinicians worldwide.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Dexcom Inc stock.
Overvalued: intrinsic value $55.64 per share, market price $85.98, margin of safety -54.5% (as of 2026-10-19).
Discounting its cash flows at 11.3% (average of 3 methods) values the shares at $55.64; the price of $85.98 is 55% above that value, and 70% of that value comes from beyond year five.
Leak Score: 68/100 on 11 of 12 signals (Faint Leak).
17 more funds hold it; the full list is part of the paid plan.
All 142 Medical Devices stocks
29 more in this industry show a wider margin of safety.
DXCM is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 11.3% (average of 3 methods) values the shares at $55.64; the price of $85.98 is 55% above that value, and 70% of that value comes from beyond year five.
$55.64 per share (as of the 2026-10-19 close), against a market price of $85.98. That is a margin of safety of -54.5%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
68 out of 100, which we rate "Faint Leak", on 11 of 12 value investing signals.